anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An objective of the present invention is to provide a cube to inform a user of family history, capable of interestingly and easily informing a user of information about family history, and memorizing the same for a long time. To this end, according to the present invention, the cube to inform a user of family history informs the user of information about six family historic diseases through six main surfaces. Each main surface includes nine unit surfaces arranged by three columns X three lines. A first column among the three columns sequentially includes three lines of the absence of a corresponding family historic disease, the presence of a corresponding family historic disease, and the presence of a corresponding family historic disease. A second column among the three columns sequentially includes three lines of a first disease probability of a child with respect to the same disease when only one side from a father and a mother has the corresponding family historic disease, a second disease probability of the child with respect to the same disease when both of the father and the mother do not have the corresponding family historic disease, and a third disease probability of the child with respect to the same disease when both of the father and the mother have the corresponding family historic disease. A third column among the three columns sequentially includes three lines of a related disease caused from the corresponding family historic disease, handicap or death details to be generated when the related disease is continued, and insured details when at least one among the related disease, the handicap, and the death occurs in order.
Each 5 g dose of LOKELMA contains approximately 400 mg of sodium, but the extent of absorption by the patient is unknown. In clinical trials of LOKELMA in patients who were not on dialysis, edema was observed and was generally mild to moderate in severity and was more commonly seen in patients treated with 15 g once daily. Monitor for signs of edema, particularly in patients who should restrict their sodium intake or are prone to fluid overload (e.g., heart failure or renal disease). Advise patients to adjust dietary sodium, if appropriate. Increase the dose of diuretics as needed [see Adverse Reactions (6)].

In a clinical trial of LOKELMA in patients on chronic hemodialysis in which most patients were treated with doses of 5 to 10 g once daily on non-dialysis days, there was no difference in the mean change from baseline in interdialytic weight gain (a measure of fluid retention) between the LOKELMA and placebo groups.
The family of ruthenium compounds that is subject of the present patent was found to exhibit great potential as pharmaceutical agents for the treatment of cancer condition. In fact, the present compounds which structure is based on piano stool Μ(η 5 - ciclopentadienyl ) (M=Ru, Fe) possessing compulsory sigma bonded heteroaromatic ligands to treat tumor and /or metastasis. These compounds displayed very high efficiency   in vitro   in what concerns their cytotoxicity against a wide range of tumor cells significantly surpassing the activity of the benchmark metallodrug cisplatin currently in clinical use. In addition, we have identified biological targets involved in th mode of action of the ruthenium compounds such as, PARP-1 (a Poly- (adenosine diphosphate (ADP) -ribose) polymerase enzyme) and cell regulatory proteins (cytochrome C and ubiquitin). Although DNA is not the main target of the ruthenium compounds, their interaction with DNA was proved by different approaches. These agents bind to albumin which can provide a vehicle for their transport in the blood stream without loss of activity. Overall this family of compounds encloses a panel of highly promising new anti-tumor ruthenium agents with a large spectrum of activity.
Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA.

In a randomized study of patients with nmCRPC (ARAMIS), ischemic heart disease occurred in 3.2% of patients receiving NUBEQA and 2.5% receiving placebo, including Grade 3-4 events in 1.7% and 0.4%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA and 0.2% receiving placebo. 

In a randomized study of patients with mHSPC (ARASENS), ischemic heart disease occurred in 3.2% of patients receiving NUBEQA with docetaxel and 2% receiving placebo with docetaxel, including Grade 3-4 events in 1.3% and 1.1%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA with docetaxel and 0% receiving placebo with docetaxel. 

Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for Grade 3-4 ischemic heart disease.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of benzofuryl-pyrone. Invention describes derivatives of benzofurylpyrone of the general formula (I):   where radicals R 1 , R 2 , R 3 , R 4  are given in claim 1 of the invention claim. Invention describes also pharmaceutical composition based on compounds of the formula (I), enhancer of lipid metabolism, inhibitor of biosynthesis of triglycerides, agent reducing blood triglycerides content, agent enhancing content of HDL (high-density lipoproteins), agent used for prophylaxis of atherosclerosis and agent used for treatment of atherosclerosis. Invention provides synthesis of novel compounds eliciting useful biological properties. EFFECT: valuable medicinal and biochemical properties of compounds. 32 cl, 1 tbl, 315 ex
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by functional deficits in three domains: social interaction, communication, and stereotypic behavior. Prevalence has been estimated to be approximately 1/166 children and the public health impact is significant. ASD clearly has a genetic component; however, identification of specific etiologies has been complicated by the heterogeneous nature of ASD. One approach to minimize this problem is to define endophenotypes that can subcategorize ASD patients. Based on our work with Smith-Lemli-Opitz syndrome, we have investigated whether alterations in cholesterol homeostasis may contribute to ASD. We found in 200 ASD subjects that 23% of subjects had serum cholesterol levels less than or equal to 2.28th centile and 9% had levels greater than or equal to 97.72nd centile. Analysis of the sterol profile suggested that the hypocholesterolemia was due to a synthetic defect rather than decreased oral intake. Thus we hypothesize that ASD patients with abnormal cholesterol levels will have polymorphisms or mutations of either genes involved in cholesterol homeostasis or genes encoding proteins whose function is altered by changes in cholesterol levels. To test this hypothesis we propose to 1) use serum cholesterol levels to define ASD endophenotypes and 2) to perform genomic resequencing of all known exons in hypo- and normocholesterolemic ASD patients.
Children (10 to 14 years) will be invited to come to a 1.5 hour laboratory assessment with a parent (most likely, mothers). We will gather parent-reported and children\'s self-reported avoidant and engaged cognitive ER strategies, worded with third or first person, respectively. \"Short form\" versions will be used to reduce burden for children. The Emotion Regulation Questionnaire for Children and Adolescents provides a 6 item reappraisal scale and a 4 item expressive suppression scale. The Avoidance and Fusion Questionnaire for Youth - Short Form provides an 8-item measure of experiential avoidance. The extended version of the Children\'s Response Styles Questionnaire provides a 5 item scale of problem-solving (also, \"reflection\") and a 5 item scale of rumination (also, \"brooding\"). Mothers will complete the Children\'s Responses to Feelings Checklist, which asks about these ER strategies in response to specific emotions, to examine specificity to threat (uncertainty/fear).

The investigators will also assess \"in-vivo\" use of cognitive ER strategies by using an ER strategy interview after children experience uncertainty via laboratory procedures. Children will watch a 2-minute clip from a live-action movie validated to elicit emotion in the domain of threat with school-aged children. The primary experimenter will interview the child about the cognitive ER strategies they used using open-ended questions with subsequent prompts to allow reports of multiple strategies. The primary experimenter will then ask closed-ended (yes/no) interview questions about each of the cognitive ER strategies of focus. Children will also complete two 5 minute tasks from the Laboratory Temperament Assessment Battery - Middle Childhood Version with established reliability and validity in the domain of threat. In the \"Storytelling\" task, the experimenter will instruct the child to stand and tell a story about the previous day in front of them and an unfamiliar research assistant (RA), enacting a series of standardized pauses and prompts until the child indicates they are finished. In the \"Mask\" episode, the child enters a room to see an adult RA wearing a mask resembling a disfigured face. The RA completes a standardized script of statements and pauses, finally taking off the mask and engaging the child in a friendly manner. The primary experimenter will repeat the ER strategy interview for the tasks. Auxiliary ER-relevant outcomes may supplement the primary focus on cognitive ER strategies. Behavioral tasks (Storytelling, Mask) can be coded for behavioral ER strategies (distraction, self-soothing, bids to experimenter). The investigators possess the necessary equipment and software for recording and analysis of children\'s ECG and respiration to serve as physiological indicators of ER. As an additional indicator of family emotional environment, the child and mother will be prompted to converse about the activities in the lab.
BACKGROUND AND AIMS: The course of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is unpredictable. The utility of markers, including liver biopsy, is undefined.
METHODS: A prospective cohort, including protocol liver biopsies, was enrolled to address these questions.
RESULTS: We enrolled 96 homozygous ZZ AATD adults prospectively at three US sites with standardized clinical evaluations, and protocol liver biopsies. Fibrosis was scored using Ishak (stages 0-6). Also, 51% of the 96 subjects had Ishak score >1 fibrosis (49% Ishak 0-1, 36% Ishak 2-3 and 15% ≥4). Elevated aspartate aminotransferase (AST) more than alanine aminotransferase (ALT), high body mass index (BMI), obesity, AST platelet ratio index and elevated serum Z alpha 1 antitrypsin (AAT) polymer levels were associated with increased fibrosis. Steatosis did not correlate to fibrosis. Increased fibrosis was associated with increased mutant Z polymer globular inclusions (p = .002) and increased diffuse cytoplasmic Z polymer on biopsy (p = .0029) in a direct relationship. Increased globule Z polymer was associated with increased serum AST (p = .007) and increased periportal inflammation on histopathology (p = .004), but there was no relationship of Z polymer hepatocellular accumulation with ALT, gamma glutamine transferase, inflammation in other parts of the lobule, necrosis or steatosis. Serum Z polymer levels were directly correlated to hepatic Z protein polymer content. Lung function, smoking and alcohol consumption patterns were not associated with fibrosis.
CONCLUSION: In AATD high BMI, obesity and elevated AST are associated with increased fibrosis. Liver biopsy features are correlated to some serum tests. Serum Z AAT polymer levels could be a future biomarker to detect fibrosis early and is directly correlated to liver Z content.
Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.
BACKGROUND: Studies have shown that in hypertensive patients, chronic kidney disease (CKD) is associated with a poor prognosis. Inflammation is a highly important factor in the progression of CKD. Detecting systemic inflammation and intervening promptly in patients with hypertension may help reduce the risk of CKD. The systemic inflammatory response index (SIRI) is a tool used to measure the systemic inflammatory response, but its relationship with CKD in patients with hypertension remains uncertain.
METHODS: We utilized data from the National Health and Nutrition Examination Survey (NHANES), which was conducted between 1999 and 2018. The analysis included a total of 20,243 participants, categorized into three groups based on SIRI tertiles. Logistic regression analysis and restricted cubic spline analysis were used to examine the relationship between the SIRI and CKD.
RESULTS: In patients with hypertension, there was a notable relationship between the SIRI and the odds of developing CKD. After full adjustment, there was a 31% greater likelihood of developing CKD associated with each incremental increase of 1 unit in the SIRI (OR: 1.31, 95% CI: 1.24-1.39, p < 0.001). The groups with greater SIRI values exhibited greater odds of developing CKD than did the T1 group (T2: OR: 1.20, 95% CI: 1.04-1.38, p = 0.015; T3: OR: 1.69, 95% CI: 1.47-1.94, p < 0.001).
CONCLUSION: A high SIRI is associated with an increased risk of CKD in hypertensive patients. The greater the SIRI is, the greater the risk of CKD in hypertensive patients.
INTRODUCTION: Myocardial infarction (MI) is a critical emergency condition that affects all aspects of health. Patients with MI need specialized care in the Coronary care unit (CCU). The main goal of care is to ensure their comfort, which can be significantly affected by their illness and hospitalization. This study aims to explore MI patients' perceptions of support network challenges to ensure comfort in the CCU.
METHODS: A qualitative approach was adopted, and semi-structured interviews and notes were used for collecting data between 2020 and mid-2021. The participants were 27 MI patients in our country who had been hospitalized in the CCU of the University Heart Hospital. They were selected using purposive sampling. The data were analyzed using conventional content analysis by Graneheim and Lundman.
FINDINGS: The results of this research were revealed in the form of a "support network" theme comprising five categories: "Physical support", "Mental occupations", "Presence of peers", "relatives support "and "Spiritual strategies".
CONCLUSION: The study results showed that MI patients, in critical condition, receiving care, and hospitalized in the CCU require continuity in their support network to ensure comfort. The inconsistency between the components of each dimension leads to the challenge of ensuring comfort.
The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
FIELD: medicine, steroids. SUBSTANCE: invention describes relatively low serum progesterone levels, from 1 to 6 ng/ml, that can be used for prophylaxis of development of endometrium cancer. Vaginal delivery of progesterone using tampon made of cross-linked polycarboxylic polymer provides this low level of progesterone in serum and also provides the complete secretory transformation of endometrium that indicates the effectiveness of progesterone. These low levels of serum progesterone will decrease risk of development of breast cancer in women that are subjected for substitution therapy and to minimize possibility of manifestation of other undesirable adverse effects associated with progesterone. EFFECT: improved new method of progesterone delivery. 17 cl, 3 dwg, 1 ex
The primary purpose of this study is to examine the effects of increased healthy protein intake (25% of daily caloric intake as protein; 25% as healthy fats and oils; 50% as complex, unrefined carbohydrates) consumed as 6 small meals during the day in combination with exercise training 4 times per week, over a 16 week period in 25 overweight, but healthy males and females (30-60 yrs old). A secondary purpose is to compare the effects of consuming two of the 6 small meals during the day comprised of whole food protein source servings 20g/serving) with a matched group consuming whey protein for 2 daily protein servings (20g/serving). In the case of both groups, 1 serving will be consumed immediately following exercise \[within 30 minutes\] and 1 serving will be consumed 2 hours before going to bed. On non-exercise days, all participants will continue to consume 6 small meals per day in the same ratio of 25% lean protein, 25% healthy fats and oils, and 50% complex, unrefined carbohydrates but the groups will differ only in the composition of the last meal of the day consumed 2 hours before going to bed in which one group will consume protein (20g/serving) as whole food protein sources and the other group will consume a single serving of a whey protein supplement. The primary purpose of this study is to quantify changes in the following health outcomes at baseline and 16 weeks: total body muscle mass and fat mass (iDXA); abdominal fat mass (most highly related to cardiovascular and metabolic disease risk); blood sugar (glucose); blood lipids; insulin, aerobic fitness (assessed with a submaximal exercise test); and muscular strength (measured by 1 repetition maximum (RM) of the chest and leg press). The following additional measures will be assessed at baseline and 16 weeks: waist circumference; body weight, heart rate, blood pressure, and hunger (Visual Analog Scales).
The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
Two different methods are used in measuring muscle strength via a Hand Held Dynamometer; the "break test" and the "make test" . During these tests, the examiner and subject play opposite roles. During the make test, the subject applies maximal force against the examiner and the position is maintained by the examiner. During the break test, the subject holds the position of the muscle being evaluated and the examiner pushes until the subject's maximal force is overcome. In the two tests, force is applied differently; the dynamometer receives different amounts of force, and different results may be generated. Therefore, the aim of this study was to compare the reliability of intrinsic foot muscle strength assessment with break and make test in healthy young subjects.
The invention relates to a medicinal composition treating haemorrhoids and a preparation method thereof. The medicinal composition is prepared from, by weight, obtuseleaf erycibe stem, anisetree bark, Polygonum aviculare, Centipeda minima, Ligusticum sinense, aster, long-noded pit viper, gekko, flos farfarae, semen melo, Rabdosia rubescens and cynomorium songaricum. The preparation method comprises the steps of stir-frying, aqueous extraction and the like. For 720 haemorrhoids treatment cases, the total effective rate reaches 96.0%. The treatment effect is obvious. No negative effect, side effect and toxic effect are found. The medicinal composition  has obvious effect in treating haemorrhoids of patients, and has good promotion value.
The invention provides a plant extract for preparing health care products or drugs for treating fever of children. The plant extract is a mixture consisting of radix isatidis, folium isatidis, honeysuckle, fructus forsythiae, fructus gardeniae, cortex moutan, radix scutellariae, radix bupleuri, earthworms and a herba lophatheri extract according to any proportion, and the mixture is the extract prepared by mixing the traditional Chinese medicine plants or prepared by firstly and respectively preparing traditional Chinese medicine extracts and then mixing the extracts. The invention further provides application of the plant extract in preparation of health care products or drugs for treating fever of children. The plant extract is a pharmaceutical preparation prepared from pharmaceutically acceptable auxiliary materials. The pharmaceutical preparation is dropping pills, tablets, capsules, granules or other conventional pharmaceutical preparations. A preparation process of the plant extract is rigorous and combines with a traditional Chinese medicine theory and clinical experiences for many years, and the plant extract is scientific and reasonable in composition, good in targeted treatment and remarkable in treatment effect.
PURPOSE:To provide a hair-improving agent composed of an antibody having immunoreactivity to a protein constituting keratin-type intermediate filament of human hair, capable of improving the breaking strength of hair and effective for improving the gloss, softness, feeling, etc., of the hair. CONSTITUTION:A protein constituting keratin-type intermediate filament obtained from the human hair, etc., is extracted with a solution containing a reducing agent and a modifying agent. The obtained protein constituting keratin-type intermediate filament is insolubilized by the removal of the reducing agent, the addition of an organic solvent or the modification of the protein to obtain a coagulum. An antibody is produced by immunizing mammals or birds with the coagulum and the antibody is used as a component of the objective hair-modifying agent. The antibody has strong affinity to a completely keratinized hair and specifically binds to the hair. The hair-modifying agent can be used in the form of shampoo, rinse, etc., by compounding to a composition for hair.